Jefferies Financial Group Inc. Purchases Shares of 140,000 Eyepoint Pharmaceuticals, Inc. $EYPT

Jefferies Financial Group Inc. purchased a new position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 140,000 shares of the company’s stock, valued at approximately $1,994,000. Jefferies Financial Group Inc. owned about 0.17% of Eyepoint Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in EYPT. State of Alaska Department of Revenue acquired a new position in shares of Eyepoint Pharmaceuticals during the third quarter valued at about $50,000. Tower Research Capital LLC TRC grew its position in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares in the last quarter. Raymond James Financial Inc. grew its position in Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after buying an additional 1,177 shares in the last quarter. Inceptionr LLC bought a new position in Eyepoint Pharmaceuticals during the second quarter valued at about $131,000. Finally, New York State Common Retirement Fund raised its holdings in Eyepoint Pharmaceuticals by 17.3% in the 3rd quarter. New York State Common Retirement Fund now owns 12,214 shares of the company’s stock valued at $174,000 after acquiring an additional 1,800 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on EYPT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Chardan Capital boosted their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Citigroup upped their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. TD Cowen raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Finally, HC Wainwright lifted their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $32.20.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.46% of the stock is currently owned by corporate insiders.

Eyepoint Pharmaceuticals Stock Down 3.4%

Shares of EYPT opened at $14.92 on Thursday. The company has a 50-day moving average price of $15.49 and a two-hundred day moving average price of $14.45. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -4.72 and a beta of 1.72. Eyepoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, March 4th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The company had revenue of $0.62 million during the quarter, compared to the consensus estimate of $1.01 million. Equities research analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Eyepoint Pharmaceuticals Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.